Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
Dasatinib Added to Intensive Chemotherapy Fails to Improve Survival in CBF-AML
Adding Dasatinib to Chemo Does Not Help CBF-AML Patients
A phase 3 randomized trial in 202 adults with core-binding factor acute myeloid leukemia (CBF-AML) found adding dasatinib to intensive chemo…
Adding dasatinib to standard chemotherapy did not improve survival for adults with core-binding factor acute myeloid leukemia and increased …
In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04.
Reduced transplant use showed similar outcomes in children with Philadelphia chromosome-positive leukemia
This single-arm Phase 2 trial evaluated chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease in 41 eligibl…
Children with a specific leukemia type achieved similar survival rates without stem cell transplants, offering a less intensive treatment op…
Dasatinib and Quercetin Show Promise in Improving Gait Speed in HIV-Associated Frailty
Can a New Drug Combination Help Older Adults with HIV Regain Strength?
Phase II trial of dasatinib and quercetin (D+Q) in 82 HIV+ frail/prefrail adults shows potential in improving gait speed. Primary endpoint: …
A new trial tests if two drugs help older adults with HIV regain strength and walk better after years of frailty.